Clinical trials: Acute Non-Lymphocytic Leukemia
Acute Myeloid Leukemia
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
This is an international multicenter open label randomized phase III trial in children with relapsed and refractory acute myeloid leukemia (AML) such a disease.
- Trial name
- NCT00186966
- Testing
- Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome), Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan, Hematopoietic stem cell transplant
- Where
- United States
- Volunteers
- 394 people
- Sponsor
- Dutch Childhood Oncology Group
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for…
- Conditions
- Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT05088356
- Testing
- Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Stanford University
Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of universal chimeric antigen receptor-modified AT19 cells in patients with relapsed or refractory hematological malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, B-cell Lymphoma
- Trial name
- NCT04796688
- Testing
- Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
- Where
- 2 sites in China
- Volunteers
- 27 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Acute Myeloid Leukemia
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML
This study evaluates the effect of pembrolizumab on the duration of remission in acute myeloid leukemia. Pembrolizumab is given after complete remission is obtained in those with AML at least 60 years old who are not candidates…
- Trial name
- NCT02708641
- Testing
- pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Michael Boyiadzis
Leukemia
Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
The purpose of this study is to determine the pharmacokinetics (PK) of decitabine administered to patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- Trial name
- NCT01378416
- Testing
- Decitabine (Dacogen)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Eisai Inc.
Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia
The clonoSEQ® Watch Registry
This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
- Trial name
- NCT04545333
- Testing
- clonoSEQ Assay
- Where
- 14 sites in United States
- Volunteers
- 465 people
- Sponsor
- Adaptive Biotechnologies
Acute Myeloid Leukemia, Myelodysplastic Syndrome
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
This phase I trial studies the side effects and best dose of anti-cluster of differentiation (CD)47 monoclonal antibody Hu5F9-G4 in treating patients with haematological malignancies including acute myeloid leukemia that has…
- Trial name
- NCT02678338
- Testing
- Hu5F9-G4
- Where
- 5 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Leukemia, Leukemia, Myeloid
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine or azacitidine in AML and intermediate or high- risk MDS patients…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
- Trial name
- NCT03066648
- Testing
- Decitabine, PDR001, MBG453
- Where
- 11 sites in United States, Australia and 6 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) .
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes
- Trial name
- OPTIMIZE (NCT06001385)
- Testing
- Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT)
- Where
- 32 sites in United States
- Volunteers
- 313 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Acute Myeloid Leukemia
Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
The hypothesis is that the replacement of the standard fludarabine and cytarabine based therapy by azacytidine could result in an improvement of RFS and OS rates in the experimental arm.
- Trial name
- FLUGAZA (NCT02319135)
- Testing
- Azacitadine, Fludarabine, Cytarabine
- Where
- Spain
- Volunteers
- 289 people
- Sponsor
- PETHEMA Foundation
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes.
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT03959085
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration
- Where
- 231 sites in United States, Australia and 3 more
- Volunteers
- 5,951 people
- Sponsor
- Children's Oncology Group
Cancer, Acute Lymphoblastic Leukemia
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Study Title: A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention for Adolescents and Young Adults with Cancer Study Population and Sample Size: Two cohorts of Adolescent and…
- Conditions
- Cancer, Acute Lymphoblastic Leukemia, Lymphoma, Sarcoma
- Trial name
- NCT02340884
- Testing
- Promoting Resilience In Stress Management (PRISM)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Seattle Children's Hospital
Acute Myeloid Leukemia
Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia
Treatment of acute myeloid leukemia (AML) consists in two main phases: induction and consolidation. Standard chemotherapy combination for induction treatment associates cytarabine (AraC), a nucleoside analog, and an anthracycline…
- Trial name
- NUCLARA (NCT03234985)
- Testing
- Biological analyses
- Where
- France
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Acute Myeloid Lukemia
Ponatinib for FLT3-ITD Acute Myelogenous Leukemia
This project is part of a joint ALFA and GOELAM strategy aiming to improve the survival of patients with newly diagnosed Acute Myeloid Leukemia (AML) aged 18-70 years.
- Trial name
- PONATINIB-AML (NCT02428543)
- Testing
- Ponatinib and Cytarabine
- Where
- 37 sites in France
- Volunteers
- 49 people
- Sponsor
- Versailles Hospital
Relapsed AML, T(8;21)
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
In this multi-center, open-label, no control,prospective clinical trial, a total of 30 relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation patients will be enrolled.
- Conditions
- Relapsed AML, T(8;21), C-KIT Mutation
- Trial name
- NCT03560908
- Testing
- Dasatinib
- Where
- China
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine.
- Trial name
- NCT06561152
- Testing
- Tagraxofusp, Cladribine (CLAD), Cytarabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Leukemia
Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as flavopiridol use different ways to stop cancer cells from dividing so…
- Trial name
- NCT00064285
- Testing
- alvocidib, imatinib mesylate
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Virginia Commonwealth University
Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Trial name
- NCT00079404
- Testing
- tanespimycin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
AML (Acute Myelogenous Leukemia
Fitness in Elderly AML Patients
The study aims to evaluate the outcome of patients (overall survival) who received treatments commensurate with the proposed "Fitness" parameters compared to that of patients whose treatment differed either in the direction of…
- Trial name
- AML-FITNESS (NCT07598838)
- Testing
- Fitness Categories: FIT, UNFIT and FRAIL
- Where
- Italy
- Volunteers
- 725 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
This phase Ib trial is to find the side effect and best dose of navitoclax when given together with venetoclax and decitabine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to…
- Trial name
- NCT05222984
- Testing
- Decitabine, Navitoclax, Venetoclax
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.